A new study used flow cytometry to compare phosphorylation levels of intracellular epitopes in peripheral blood mononuclear cells from patients with psoriasis in clinical remission who were treated with reference infliximab versus healthy controls, and further evaluated whether a switch from reference infliximab to biosimilar CT-P13 affected intracellular phosphorylation patterns.
Biologic treatments, including anti—tumor necrosis factor (anti-TNF) agents, can significantly improve psoriasis, but come at a high cost. While biosimilar therapies help to control the cost of biologic treatment, differences in manufacturing of innovator biologics and biosimilars have raised concerns about the potential to impact biological activity, efficacy, and tolerability.
A new study, published in the British Journal of Dermatology, used flow cytometry to compare phosphorylation levels of intracellular epitopes in peripheral blood mononuclear cells (PBMC) from patients with psoriasis in clinical remission (n = 25) who were treated with reference infliximab versus healthy controls (n = 19), and further evaluated whether a switch from reference infliximab to biosimilar CT-P13 affected intracellular phosphorylation patterns.
The researchers, led by Anders Krough Aarebrot, measured phosphorylation in PBMC before and after TNF stimulation in cells collected at inclusion, 3 months, and 12 months. Twenty-two patients were then randomized to either continue treatment with reference infliximab or switch to CT-P13.
The researchers found that:
The authors concluded that although there were significant differences in intracellular phosphorylation of PBMC between patients with psoriasis and healthy controls, a switch to biosimilar infliximab did not result in any significant differences, a finding that suggests that CT-P13 is noninferior to its reference.
The researchers note that this is the first study to use flow cytometry in PBMC comparing patients with psoriasis with healthy controls, or to monitor patients switching from biologics to biosimilars; they suggest that using flow cytometry might represent a promising tool to monitor disease activity and treatment efficacy in patients with psoriasis in the future.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.